• In late June 2026, Biogen announced it would present new clinical, biomarker and safety data from its Alzheimer’s portfolio at AAIC 2026 in London, including Phase 2 CELIA results for tau‑targeting antisense therapy diranersen and expanded real‑world evidence on LEQEMBI, following the FDA’s 2025 Fast Track designation for diranersen.
• The breadth of upcoming diranersen and LEQEMBI data, spanning mechanism, administration routes and three‑year real‑world use, could materially influence how investors assess Biogen’s long‑term Alzheimer’s treatment potential and portfolio balance.
• We’ll now examine how the forthcoming diranersen Phase 2 data release at AAIC 2026 may reshape Biogen’s long‑term investment narrative.

We've uncovered the 7 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Biogen Investment Narrative Recap

To own Biogen today, you need to believe that its Alzheimer’s franchise, led by LEQEMBI and now diranersen, can offset pressure on older MS and neurology drugs while recent acquisitions in immunology add breadth rather than just cost. The AAIC 2026 readout for diranersen looks like the key short term catalyst, with Alzheimer’s data central to how the stock is valued. By contrast, rising R&D charges and index removals highlight near term earnings and sentiment risk.

The most relevant recent development alongside AAIC is Biogen’s clarification that Q2 and Q3 2026 will include roughly US$454 million of acquisition related R&D charges, tied to deals like Apellis and RayThera. These costs can make near term earnings look weaker just as investors are weighing diranersen’s Phase 2 profile and LEQEMBI’s three year real world data, sharpening the trade off between funding future growth and protecting current profitability around the AAIC catalyst window.

Yet while the Alzheimer’s updates may be encouraging, investors should also be aware that...

Biogen's narrative projects $10.7 billion revenue and $2.2 billion earnings by 2029.

Uncover how Biogen's forecasts yield a $219.27 fair value, in line with its current price.

Exploring Other Perspectives

The most bearish analysts saw Biogen’s revenue shrinking around 4.5 percent a year to about US$8.6 billion by 2029, so if AAIC data or pricing trends differ from expectations your view on Alzheimer’s adoption and payer pushback could end up very different from theirs.

Explore 6 other fair value estimates on Biogen - why the stock might be worth over 2x more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Biogen research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Biogen research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Biogen's overall financial health at a glance.

Looking For Alternative Opportunities?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• The future of work is here. Discover the 29 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 16 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.